China Allergy Therapeutics Market Analysis

China Allergy Therapeutics Market Executive Summary

China Allergy Therapeutics Market was valued at $1865 Mn in 2022 and is estimated to reach $3426 Mn in 2030, exhibiting a CAGR of 7.9% during the forecast period.

Environmental substances known as allergens occasionally trigger an immunological reaction called allergy. Common allergens include dust mites, pollen, mildew, and certain foods, including milk, eggs, soy, and almonds. From minor symptoms like a runny nose and itchy eyes to more dangerous ones like anaphylaxis, which can result in unconsciousness and breathing difficulties, allergy reactions can take many different forms. Immunotherapy, avoiding allergens, and prescription drugs such as nasal corticosteroids and antihistamines are a few possible treatment choices.

The incidence of food allergies in China ranges from 4.0% to 8.2%, with individual prevalences of 1.9%, 1.5%, 1.4%, 1.3%, and 1.3% for regularly identified allergic foods like mango, shrimp, egg, milk, and crab, respectively. About 23.2% of urban children and 17.6% of adults in big cities suffer from allergic rhinitis (AR), a condition that is more common in northern than southern regions. Asthma prevalence is higher in urban than rural settings, affecting 4.2% of adults and 6.6% of children in urban areas nationally. Cases of atopic dermatitis (AD) are rising by 25.65% in China, outpacing the global average. Atopic dermatitis affects 34.1% of children in metropolitan areas. Adults have an overall incidence of food allergies ranging from 4.0% to 8.2%; however, children have an increased prevalence from 3.5% to 11.1%. Common allergens include milk, crab, shrimp, mango, and eggs.

A major advancement was announced by China Biologic Products, Inc. (CBP) on the phase II clinical trial results for CB010, a long-acting recombinant humanized anti-IgE antibody intended to treat severe persistent allergic rhinitis (SAR). The trial results, which are expected to be released in early 2024, could potentially advance therapy choices for this difficult allergy illness.

With the successful conclusion of phase II clinical trials for JS016, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) created for the treatment of peanut allergy, Shanghai Junsun Pharmaceuticals accomplished an impressive feat. The business is about to start phase III trials, which is an important step toward possible improvements in the treatment of peanut allergies.

Market Dynamics

Market Growth Drivers

Prevalence of Allergies: The demand for efficient allergy treatment medications is developing due to an increase in the prevalence of respiratory allergies and allergic disorders, including hay fever. Increased allergy prevalence may be attributed to urbanization, lifestyle changes, and environmental causes.

Rapid Urbanization and Environmental Changes: Urbanization and environmental changes, particularly pollution and exposure to new allergens, can contribute to an increased incidence of allergies. The need for allergy treatment drugs is being driven by the possibility of an increase in allergic reactions as more individuals relocate to metropolitan regions.

Advancements in Allergen Immunotherapy (AIT): The development of innovative substitutes, such sublingual immunotherapy (SLIT) patches and pills, raises the prospect of more durable relief with fewer side effects. This opens up new market niches for these innovative therapies.

Market Restraints

Long-Term Treatment Commitment: Allergen immunotherapies sometimes require a long-term commitment, ranging from months to years, in order to achieve the optimum benefits. This may be challenging for people who struggle to follow treatment programs or who might not see relief straight away.

High Cost of Treatment: Some people may find allergy treatment to be expensive due to its high cost, particularly when it comes to AIT techniques like immunotherapy injections and SLIT tablets. This could limit business penetration and accessibility. Many of the most effective allergy medications currently available, such as biologics and sublingual immunotherapy, are unaffordable for a sizable section of the population due to their high cost. Patients may not receive the best care possible as a result of the pricing barrier since fewer medications will be approved by the market.

Cultural and Behavioural Factors: Some communities preference for conventional drugs or home remedies over modern therapies may hinder market penetration. Reduced community awareness may make it more difficult to recognize and understand allergy symptoms, which could delay diagnosis and treatment. Using non-pharmaceutical techniques, such as air filters, to reduce allergens and/or eliminate allergy symptoms is becoming more popular despite these disadvantages.

Healthcare Policies and Regulatory Landscape

In order to guarantee the safety and effectiveness of pharmaceuticals, especially allergy treatments, the National Medical Products Administration (NMPA), a crucial regulatory organization, oversees their approval, registration, and post-market surveillance. Before approving a product for marketing, the NMPA division's Center for Drug Evaluation (CDE) performs extensive evaluations. The National Health Commission (NHC), which formerly comprised the Ministry of Health (MOH), is involved in the development of healthcare policies and strategic planning. A division of NMPA, the China National Drug Administration (CNDA) is responsible for overseeing drug registration and adherence to legal requirements. The reimbursement policies that affect market access for allergy treatment pharmaceuticals are determined in part by the National Healthcare Security Administration (NHSA) and the Healthcare Security Administration (HSA).

Competitive Landscape

Key Players

• Jiangsu Hengrui Medicine Co.
• BeiGen
• CSPC Pharmaceutical Group Co.
• Yunnan Baiyao Group Co.
• Sinopharm Group Co.
• Guangzhou Fuluo Pharmaceutical Co.
• Hunan Haier Pharmaceutical Co.
• Shandong Lukang Pharmaceutical Group Co.
• North China Pharmaceutical Group Corporation
• Shanghai RAAS Pharma Co.